 |
Publisher: Peytchinski Publishing
ISSN: 1312-773X (Online)
Issue: 2018, vol. 24, issue3
Subject Area: Medicine
-
DOI: 10.5272/jimab.2018243.2186
Published online: 27 September 2018
Original article
J of IMAB. 2018 Jul-Sep;24(3):2186-2189
USE OF IMMUNOBLOT IgM IN PATIENTS WITH SEROLOGICAL AND CLINICAL EVIDENCE OF PRIMARY EBV INFECTION AND REACTIVATION
Tsvetelina Kostadinova1
, Liliya Ivanova2,3, Milena Bozhkova2,4, Denitsa Tsaneva2, Tatina Todorova5, Zhivka Stoykova2,3,,
1) Education and Research Sectors of Medical Laboratory Assistant, Medical College, Medical University, Varna, Bulgaria.
2) Department of Microbiology and Virology, Medical University, Varna, Bulgaria.
3) Laboratory of Clinical Virology, University hospital St. Marina, Varna, Bulgaria
4) Laboratory of Clinical Microbiology, University hospital St. Marina, Varna, Bulgaria
5) Department of Preclinical and Clinical Sciences, Faculty of Pharmacy, Medical University, Varna, Bulgaria.
ABSTRACT:
Purpose: Anti-VCA IgM is a marker for establishing primary infection with Epstein-Barr Virus (EBV), it usually appears in combination with anti-VCA IgG. It has been shown that there is a risk of non-specific IgM reactivity due to cross-reactions, interference with rheumatoid factor or autoantibodies. These antibodies may also occur during reactivation. In these cases, Immunoblot based tests may be useful to confirm the ELISA result. We compared the results of anti-VCA IgM in ELISA and Immunoblot IgM in patients with evidence of primary EBV infection (infectious mononucleosis, IM) and/or reactivation/reinfection.
Materials/Methods: We examined 32 serum samples with commercial immunoblot (Euroline Anti-EBV Profile 2 (IgM), Euroimmun, Germany). Samples were tested primarily for anti-VCA IgM/IgG in ELISA. Patients with IM were 11, and those with probable reactivation/reinfection - 21.
Results: We found positive results at 31.3% (95% CI: 16.1% -50.0 %, n = 10) of all subjects. Patients with IM and isolated anti-VCA IgM in ELISA (81.8%) were negative in Immunoblot IgM. Positive in Immunoblot IgM was 38.1% (n = 8) of the patients with suspected reactivation. We confirmed a primary infection in three of them due to the low avidity of anti-VCA IgG and missing anti-EBNA1 IgG. In five of the patients, the presence of anti-VCA IgM may be interpreted as reactivation/reinfection.
Conclusion: Patients with IM and isolated anti-VCA IgM models in ELISA were not confirmed in the Immunoblot test. Approximately 43% of patients of possible reactivation was also negative in the test.
Keywords: Epstein-Barr virus, anti-VCA IgM, Immunoblot IgM, Infectious mononucleosis, EBV reactivation,
- Download FULL TEXT /PDF 540 KB/
Please cite this article as: Kostadinova T, Ivanova L, Bozhkova M, Tsaneva D, Todorova T, Stoykova Z. Use of Immunoblot IgM in patients with serological and clinical evidence of primary EBV infection and reactivation. J of IMAB. 2018 Jul-Sep;24(3):2186-2189. DOI: 10.5272/jimab.2018243.2186
Correspondence to: Tsvetelina Kostadinova, MD, PhD. Education and Research Sectors of Medical Laboratory Assistant, Medical College, Medical University – Varna; 84 Tsar Osvoboditel Blvd., Varna, Bulgaria; E-mail: ckostadinova@abv.bg
REFERENCES:
1. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000 Aug 17;343(7):481–92. [PubMed] [Crossref]
2. Kostadinova T, Ivanova L, Raykov T, Stojkova Z, Tsankova G. Seroprevalence of Epstein-Barr Virus in North-Eastern Bulgaria. ACTA Microbiol Bulg. 2016 Sep;32(3):33-8.
3. De Paschale M, Clerici P. Serological diagnosis of Epstein-Barr virus infection: Problems and solutions. World J Virol. 2012 Feb 12;1(1):31-43. [PubMed] [Crossref]
4. Gärtner BC, Hess RD, Bandt D, Kruse A, Rethwilm A, Roemer K, et al. Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. Clin Diagn Lab Immunol. 2003 Jan;10(1):78–82. [PubMed] [Crossref]
5. Hess RD. Routine Epstein-Barr virus diagnostics from the laboratory perspective: Still challenging after 35 years. J Clin Microbiol. 2004 Aug;42(8):3381-7. [PubMed] [Crossref]
6. Obel N, Høier-Madsen M, Kangro H. Serological and clinical findings in patients with serological evidence of reactivated Epstein-Barr virus infection. APMIS. 1996 Jun;104(6):424-8. [PubMed]
7. Bauer G. Simplicity through complexity: immunoblot with recombinant antigens as the new gold standard in Epstein-Barr virus serology. Clin Lab. 2001;47(5-6):223-30. [PubMed]
8. Adler B, Schaadt E, Kempkes B, Zimber-Strobl U, Baier B, Bornkamm GW. Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1. Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):437-42. [PubMed] [Crossref]
9. Maurmann S, Fricke L, Wagner H-J, Schlenke P, Hennig H, Steinhoff J, et al. Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers. J Clin Microbiol. 2003 Dec;41(12):5419-28. [PubMed]
10. Altuğlu I, Aksoy A, Zeytinoğlu A, Orman M. [Evaluation of immunoblot-based assay for detecting Epstein-Barr virus viral capsid antibodies]. [in Turkish] Mikrobiyol Bul. 2010 Apr;44(2):231-6. [PubMed]
11. Nystad TW, Myrmel H. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis. J Clin Virol. 2007 Apr;38(4):292-7. [PubMed] [Crossref].
Received: 23 May 2018
Published online: 27 September 2018